Sandoz Canada launches PrSandoz® Sacubitril-Valsartan, expanding access to heart failure treatments

• ^PrSandoz^® Sacubitril-Valsartan is generic indicated for treatment of heart failure with reduced ejection fraction (HFrEF), which currently affects approximately 375,000 Canadians¹
• As reference medicines are among the most expensive treatments, the arrival of an affordable treatment will help reduce overall healthcare costs

SAINT-HUBERT, QC, Oct. 1, 2025 /CNW/ - Sandoz Canada, a leader in affordable medicines, today announced the launch of ^PrSandoz^® Sacubitril-Valsartan, a high-quality affordable alternative to the reference medicine ^PrEntresto, approved for all its indications. This launch marks another important step in line with Sandoz Purpose of pioneering access for patients by expanding its portfolio of cardiovascular therapies for Canadian patients.

^PrSandoz^® Sacubitril-Valsartan is indicated for the treatment of heart failure with reduced ejection fraction (HFrEF) in patients with NYHA Class II or III, to reduce the incidence of cardiovascular death and heart failure hospitalisation.

The product is available in the following strengths and formats:

• 24 mg/26 mg tablets (blisters of 30)
• 49 mg/51 mg tablets (blisters of 60)
• 97 mg/103 mg tablets (blisters of 60)

Heart failure affects more than 750,000 Canadians, with nearly 100,000 new cases diagnosed each year ². It is the second leading cause of hospitalization among Canadians over 65, with direct costs estimated at more than CAD 2.8 billion annually³. Heart failure with reduced ejection fraction represents nearly half of all cases⁴.

Clinical data shows that sacubitril-valsartan significantly improves patient outcomes compared to standard therapy, with a 25% to 30% reduction in hospitalization rates⁵.

With more than 100,000 Canadians currently treated with the reference product, the introduction of a high-quality generic alternative is expected to deliver substantial savings. Indeed, according to the Canadian Institute for Health Information (CIHI), annual spending on this therapy exceeds CAD 100 million nationwide⁶, making it one of the costliest medicines for public drug plans.

"Considering the significant number of Canadians affected by heart failure, we are proud to expand our generic portfolio with the launch of ^PrSandoz^® Sacubitril-Valsartan," said Michel Robidoux, President and General Manager, Sandoz Canada. "This launch reinforces our Purpose of pioneering access for patients, delivering a cost-effective treatment option that will generate savings, while helping patients better manage their cardiovascular health."

DISCLAIMER

This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.

About Sandoz Canada

As a Canadian leader in off-patent medicines, Sandoz Canada has a product portfolio that includes over 700 generics and biosimilars spanning multiple therapeutic areas, such as anti-infective, cardiovascular, central nervous system, immunology and oncology. In 2024, 56 million Sandoz prescriptions were dispensed in Canada (source: IQVIA Compuscript TRx). Sandoz Canada employs 300 people across the country and at its head office in Saint-Hubert, Quebec. It is a trusted partner for pharmacists, physicians and hospitals for quality medicine and outstanding customer service and is committed to ensuring a reliable supply. For more information about Sandoz Canada, visit www.sandoz.ca.

About Sandoz AG

Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in affordable medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world's first oral penicillin in 1951, and the world's first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.

Follow Sandoz Canada on social media
LinkedIn https://www.linkedin.com/company/sandozcanada 

¹ Huitema, A. A., et al. (2020). Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada. CJC Open, 2(5). https://pmc.ncbi.nlm.nih.gov/articles/PMC7499363/

² Lindsay, P. et al. (2022). The State of Heart Failure Services in Canada: Finding of the Heart & Stroke National Heart Failure Resources and Services Inventory. Canadian Journal of Cardiology, 38 (10). https://onlinecjc.ca/article/S0828-282X(22)00687-0/fulltext 

³ Cook, C. et al. (2014). The annual global economic burden of heart failure. International Journal of Cardiology, 171(3). https://www.internationaljournalofcardiology.com/article/S0167-5273(13)02238-9/abstract 

⁴ Huitema, A. A., et al. (2020). Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada. CJC Open, 2(5). https://pmc.ncbi.nlm.nih.gov/articles/PMC7499363/ 

⁵ David A. Morrow (2024). Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure. JACC Journals. Volume 83, Number 12. https://www.jacc.org/doi/10.1016/j.jacc.2024.01.027

⁶ Canadian Institute for Health Information (November 7, 2024). National health expenditure trends 2024 – Snapshot. https://www.cihi.ca/en/national-health-expenditure-trends-2024-snapshot

SOURCE Sandoz Canada

Media relations contact: Sophie Levasseur, Manager, Corporate Communications, [email protected], ([phone]